α-肾上腺素能激动剂盐酸阿可乐定（ALO 2145）可减少房水流量。

Aqueous flow is reduced by the alpha-adrenergic agonist, apraclonidine hydrochloride (ALO 2145).

作者信息

Gharagozloo N Z, Relf S J, Brubaker R F

机构信息

Department of Ophthalmology, Mayo Clinic and Foundation, Rochester, Minnesota 55905.

出版信息

Ophthalmology. 1988 Sep;95(9):1217-20. doi: 10.1016/s0161-6420(88)33038-1.

DOI:10.1016/s0161-6420(88)33038-1

PMID:3062536

Abstract

Apraclonidine hydrochloride (ALO 2145), a clonidine derivative that does not cross the blood-brain barrier, was applied topically to one eye of each of 20 normal human subjects. The rate of aqueous humor flow and the permeability of the blood-aqueous barrier were measured by fluorophotometry. Four hours after administration, the flow rate in the apraclonidine-treated eyes was 35% lower than that measured in the control eyes. Three hours after instillation, the intraocular pressure (IOP) was 34% lower in the apraclonidine-treated eyes when compared with control eyes. Both these differences were statistically significant. The drug had little, if any, effect on blood-aqueous permeability.

摘要

盐酸阿可乐定（ALO 2145）是一种不会透过血脑屏障的可乐定衍生物，对20名正常人类受试者的每只眼睛进行局部用药。通过荧光光度法测量房水流出率和血-房水屏障的通透性。给药4小时后，用阿可乐定治疗的眼睛的房水流出率比对照眼睛低35%。滴注3小时后，与对照眼睛相比，用阿可乐定治疗的眼睛的眼压降低了34%。这两个差异均具有统计学意义。该药物对血-房水通透性几乎没有影响（如果有影响也是极小的）。